Research graph
References from Prognostic impact of variant allele frequency in intensively treated patients with NPM1 -mutated AML: a PETHEMA study. Local targets link to admitted publications; unresolved targets remain external evidence.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
10.1182/blood-2014-11-610543 · 2015 · External reference
Genomic classification and prognosis in acute myeloid leukemia
10.1056/nejmoa1516192 · 2016 · External reference
Unified classification and risk-stratification in acute myeloid leukemia
10.1038/s41467-022-32103-8 · 2022 · External reference
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
10.1056/nejmoa041974 · 2005 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis
10.1182/blood.2019003339 · 2020 · External reference
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
10.1182/bloodadvances.2021006242 · 2022 · External reference
Molecular minimal residual disease in acute myeloid leukemia
10.1056/nejmoa1716863 · 2018 · External reference
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
10.1038/s41467-020-19119-8 · 2020 · External reference
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
10.1002/cncr.32566 · 2019 · External reference
Clonal heterogeneity and tumor evolution: past, present, and the future
10.1016/j.cell.2017.01.018 · 2017 · External reference
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
10.1038/nature22993 · 2017 · External reference
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia
10.1038/s41467-021-27472-5 · 2021 · External reference
Effect of mutation order on myeloproliferative neoplasms
10.1056/nejmoa1412098 · 2015 · External reference
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
10.1056/nejmoa1113205 · 2012 · External reference
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
10.3324/haematol.2020.263806 · 2020 · External reference
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia
10.1002/ajh.25454 · 2019 · External reference
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
10.1182/blood-2018-01-828467 · 2018 · External reference
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study
10.1038/s41375-025-02851-9 · 2026 · External reference
Multi-modal and data-driven assessment of myeloid neoplasms refines classification across disease states
10.1158/2643-3230.bcd-25-0047 · 2025 · External reference
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML
10.1002/hem3.70060 · 2025 · External reference
NPM1-mutated AML: deciphering the molecular and clinical puzzle in the era of novel treatment strategies
10.3390/cancers17132095 · 2025 · External reference
Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia
10.1038/s41408-024-01103-w · 2024 · External reference
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
10.1182/blood.2024024310 · 2024 · External reference
Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML
10.1016/j.bbmt.2018.04.017 · 2018 · External reference
Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: where to draw the line?
10.1002/hem3.55 · 2024 · External reference
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
10.1038/s41408-024-01054-2 · 2024 · External reference
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
10.1038/s41586-024-08137-x · 2024 · External reference
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
10.1182/blood-2013-01-479188 · 2013 · External reference
Preleukemic and leukemic evolution at the stem cell level
10.1182/blood.2019004397 · 2021 · External reference
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
10.3324/haematol.2023.284601 · 2024 · External reference
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes
10.1038/s41467-019-13001-y · 2019 · External reference
Single-cell mutation analysis of clonal evolution in myeloid malignancies
10.1038/s41586-020-2864-x · 2020 · External reference
PyClone: statistical inference of clonal population structure in cancer
10.1038/nmeth.2883 · 2014 · External reference
ClonEvol: clonal ordering and visualization in cancer sequencing
10.1093/annonc/mdx517 · 2017 · External reference
